Dr. David McNeill is the Medical Director for Integrated Health Services at Ontario Shores Centre for Mental Health Sciences (Ontario Shores) and is a regular Examiner for the Medical Council of Canada. He is currently involved in three research projects. The first is a Central East LHIN funded Ontario Shores site of the study called the Diabetes Measureable Outcomes Project. This study is a large initiative to develop and implement a standardized tool for measuring both quantitative and qualitative outcomes for Diabetes Education Centre clients within the Central East LHIN. This project is also part of the preparation for roll-out of the provincial Diabetes Registry and eHealth programs. Dr. McNeill’s two additional studies are both Janssen funded extensions of multi-centre clinical trials assessing efficacy and safety of Bapineuzumab. Dr. McNeill’s future projects include a multi-centre, randomized controlled study of the safety and effects of BMS-708163 in treatment of patients with prodromal Alzheimer’s, funded by Bristol-Myers-Squibb. His current research interests include Alzheimer’s disease, as well as diabetes and cardiovascular risk modification in the mental health population. He is the recipient of the Province of Ontario ACE Award for Innovation in Healthcare Delivery and the 3M Healthcare Quality Team Award for the Ontario Shores’ Metabolic and Weight Management Clinic.
Current Research Projects:
Title: Diabetes Measurable Outcomes Project
Funding: Central East LHIN
Title: Extension of multi-centre, randomized, double-blind, placebo controlled, parallel group, efficacy and safety trial of Bapineuzumab
Title: Extension of a phase III multi-centre, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of Bapineuzumab in patients with mild to moderate Alzheimer’s disease who are Apolipoprotein E 4 Non-carriers